Arch Oncology, Inc, 2000 Sierra Point Pkwy, Fl 700, Brisbane, CA 94005, US

BryoLogyx Inc, based in Danville, CA, is a pioneering biopharmaceutical company focused on developing a new class of drugs to enhance the response rates and treatment durability of cancer immunotherapies. Leveraging recent scientific breakthroughs, BryoLogyx is capitalizing on the discovery that bryostatin, a complex natural product, stimulates tumor antigen production, thereby amplifying the immune response unleashed by cancer immunotherapy. With the invention of the first practical synthetic production method for bryostatin and analogs, the company aims to expand the horizon of immuno-oncology and make tumors "hot" for improved therapeutic outcomes. Having obtained exclusive rights from Stanford University, BryoLogyx is utilizing the method in the areas of cancer, as well as inflammatory, autoimmune, and infectious diseases, excluding neurological and CNS diseases and psychiatric disorders. Currently in preclinical development for use with immuno-oncology agents, bryostatin has demonstrated an established safety profile based on prior clinical studies involving over 1100 patients. With a commitment to advancing the field of cancer immunotherapy, BryoLogyx is poised to revolutionize the treatment landscape and contribute to the fight against cancer.Generated from the website

Ipsen

Day One Biopharmaceuticals, Inc

7 Cedar Kentfield LLC

Xojet